Olive Allergy Therapeutic Pipeline Reviewed in New Global Markets Direct Study Published at MarketPublishers.com
05 Dec 2012 • by Natalie Aster
LONDON – An estimated 10 percent of the world's population suffers from pollen allergies, causing days of poorer life quality. The pollen from olive trees is one of the most important causes of seasonal respiratory allergy, especially in the Mediterranean countries where this tree is widely distributed. Up to date, twelve allergens have been identified in olive pollen while just one allergen has been identified in olive fruit.
New research study “Olive Allergy – Pipeline Review, H2 2012” elaborated by Global Markets Direct provides an overview of the global therapeutic scenario for olive allergy. It reviews the olive allergy products under development by companies and different research organizations; reviews the products being in various phases of development – from discovery till registration; features pipeline projects on the basis of monotherapy and combined therapeutics; analyzes the olive allergy pipeline in terms of route of administration and molecule type; uncovers the discontinued projects, besides looking into the factors that drove them from pipeline. Furthermore, the emerging players with potentially strong product portfolio are identified, as well as the latest news and deals relating to the products are provided.
Olive Allergy – Pipeline Review, H2 2012
Published: November, 2012
Price: US$ 2.000,00
More Pipeline Reviews H2 2012 by Global Markets Direct Include:
- Respiratory Tract Inflammatory Disorders – Pipeline Review, H2 2012
- Skin Cancer – Pipeline Review, H2 2012
- Pain – Pipeline Review, H2 2012
- Advanced Malignancy – Pipeline Review, H2 2012
- X Chromosome Disorders – Pipeline Review, H2 2012
- Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H2 2012
- Other Ophthalmological Disorders – Pipeline Review, H2 2012
- Pancreatic Tumor – Pipeline Review, H2 2012
More new research studies by the publisher can be found at Global Markets Direct page.